Innate Pharma (IPHA) Research & Development (2019 - 2025)
Innate Pharma's (IPHA) quarterly Research & Development came in at -$50.8 million in Q4 2025, up 8.59% YoY from -$46.8 million in Q4 2024, and down 118.6% on a QoQ basis from -$23.2 million in Q2 2025.
Innate Pharma (IPHA) Research & Development (2019 - 2025) Analysis & Trends
Innate Pharma (IPHA) has 7 years of Research & Development data on file, last reported at -$50.8 million in Q4 2025.
- Quarterly Research & Development rose 8.59% year-over-year to -$50.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$160.9 million (up 11.31% YoY) and the FY2025 annual result came in at $50.8 million, down 8.59% from the prior year.
- Research & Development retreated to -$50.8 million in Q4 2025, from -$23.2 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of -$23.2 million in Q2 2025 to a low of -$60.3 million in Q4 2023.
- A 5-year average of -$41.5 million and a median of -$42.5 million in 2023 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2023 — Research & Development retreated 28.62% — and 2025, when it grew 25.82%.
- Tracing IPHA's Research & Development over 5 years: stood at -$53.8 million in 2021, then increased by 1.98% to -$52.7 million in 2022, then decreased by 14.36% to -$60.3 million in 2023, then grew by 7.85% to -$55.5 million in 2024, then grew by 8.59% to -$50.8 million in 2025.
- The last three Research & Development figures came in at -$50.8 million (Q4 2025), -$23.2 million (Q2 2025), and -$55.5 million (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.29 Bn | 131.44 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 59.49 Bn | 54.36 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 42.02 Bn | 36.92 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.79 Bn | 27.48 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.26 Bn | 9.87 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.30 Bn | 26.14 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.10 Bn | 26.26 Bn | - | 97.90 Mn |
| 10 | Innate Pharma | 203.45 Mn | 203.45 Mn | - | -50.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -50.78 Mn |
| Jun 30, 2025 | -23.23 Mn |
| Dec 31, 2024 | -55.55 Mn |
| Jun 30, 2024 | -31.31 Mn |
| Dec 31, 2023 | -60.28 Mn |
| Jun 30, 2023 | -34.25 Mn |
| Dec 31, 2022 | -52.71 Mn |
| Jun 30, 2022 | -26.63 Mn |
| Dec 31, 2021 | -53.77 Mn |
| Jun 30, 2021 | -26.25 Mn |
| Dec 31, 2020 | -59.27 Mn |
| Jun 30, 2020 | -34.69 Mn |
| Dec 31, 2019 | -87.27 Mn |
| Jun 30, 2019 | -41.11 Mn |